Trial · NCT06336603
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on IGA at Week 16. | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | 65 | percentage of participants | ||
| Percent of Total Lesion Reduction at Week 16 Compared to Baseline | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | 87.3 | Standard Deviation 11.4 | Percentage change | |
| Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | 90.5 | Standard Deviation 10.1 | percentage change | |
| Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | 84.8 | Standard Deviation 13.5 | percentage change | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Baseline | 76 | percentage of participants | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 4 | 88 | percentage of participants | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 8 | 100 | percentage of participants | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 12 | 100 | percentage of participants | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 16 | 94 | percentage of participants | |
| Tolerability Measures of Erythema Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 20 | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Baseline | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 4 | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 8 | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 12 | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 16 | 100 | percentage of participants | |
| Tolerability Measures of Dryness Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 20 | 100 | percentage of participants | |
| Tolerability Measures of Peeling Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Baseline | 100 | percentage of participants | |
| Tolerability Measures of Peeling Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 4 | 100 | percentage of participants | |
| Tolerability Measures of Peeling Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 8 | 100 | percentage of participants | |
| Tolerability Measures of Peeling Based on 5-point Severity Scale | Winlevi (Clascoterone) 1% & Adapalene 0.3% Gel | Week 12 | 100 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06336603/results